Chapter: 1INTRODUCTION

1.1.REPORT DESCRIPTION
1.2.KEY BENEFITS
1.3.KEY MARKET SEGMENTS
1.4.RESEARCH METHODOLOGY

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

Chapter: 2EXECUTIVE SUMMARY

2.1.CXO PERSPECTIVE

Chapter: 3MARKET OVERVIEW

3.1.MARKET DEFINITION AND SCOPE
3.2.KEY FINDINGS

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.MARKET SHARE ANALYSIS, 2016
3.4.PORTER’S FIVE FORCES ANALYSIS

3.4.1.MARKET DYNAMICS
3.4.2.Drivers
3.4.3.Restraints
3.4.4.Opportunities

Chapter: 4METACYCLINE MARKET, BY THERAPEUTICS

4.1.OVERVIEW

4.1.1.Market size and forecast

4.2.CHRONIC BRONCHITIS

4.2.1.Key market trends
4.2.2.Growth factors and opportunities
4.2.3.Market size and forecast

4.3.RICKETTSIAL INFECTIONS

4.3.1.Key market trends
4.3.2.Growth factors and opportunities
4.3.3.Market size and forecast

4.4.PNEUMONIA

4.4.1.Key market trends
4.4.2.Growth factors and opportunities
4.4.3.Market size and forecast

4.5.TRENCH FEVER

4.5.1.Key market trends
4.5.2.Growth factors and opportunities
4.5.3.Market size and forecast

4.6.TYPHUS

4.6.1.Key market trends
4.6.2.Growth factors and opportunities
4.6.3.Market size and forecast

4.7.Q FEVER

4.7.1.Key market trends
4.7.2.Growth factors and opportunities
4.7.3.Market size and forecast

4.8.SINUSITIS

4.8.1.Key market trends
4.8.2.Growth factors and opportunities
4.8.3.Market size and forecast

4.9.OTHERS

4.9.1.Key market trends
4.9.2.Growth factors and opportunities
4.9.3.Market size and forecast

Chapter: 5METACYCLINE MARKET, BY GEOGRAPHY

5.1.OVERVIEW
5.2.NORTH AMERICA

5.2.1.Key market trends
5.2.2.Key growth factors and opportunities
5.2.3.Market size and forecast

5.2.3.1.U.S. market size and forecast
5.2.3.2.Canada market size and forecast
5.2.3.3.Mexico market size and forecast

5.2.4.North America Metacycline Market by Therapeutics

5.3.EUROPE

5.3.1.Key market trends
5.3.2.Key growth factors and opportunities
5.3.3.Market size and forecast

5.3.3.1.Germany market size and forecast
5.3.3.2.France market size and forecast
5.3.3.3.UK market size and forecast
5.3.3.4.Italy market size and forecast
5.3.3.5.Spain market size and forecast
5.3.3.6.Rest of Europe market size and forecast

5.3.4.Europe Metacycline Market by Therapeutics

5.4.ASIA-PACIFIC

5.4.1.Key market trends
5.4.2.Key growth factors and opportunities
5.4.3.Market size and forecast

5.4.3.1.Japan market size and forecast
5.4.3.2.China market size and forecast
5.4.3.3.Australia market size and forecast
5.4.3.4.India market size and forecast
5.4.3.5.South Korea market size and forecast
5.4.3.6.Taiwan market size and forecast
5.4.3.7.Rest of Asia-Pacific market size and forecast

5.4.4.Asia-Pacific Metacycline Market by Therapeutics

5.5.LAMEA

5.5.1.Key market trends
5.5.2.Key growth factors and opportunities
5.5.3.Market size and forecast

5.5.3.1.Brazil market size and forecast
5.5.3.2.Turkey market size and forecast
5.5.3.3.Saudi Arabia market size and forecast
5.5.3.4.South Africa market size and forecast
5.5.3.5.Rest of LAMEA market size and forecast

5.5.4.LAMEA Metacycline Market by Therapeutics

Chapter: 6COMPANY PROFILES

6.1.MERCK

6.1.1.Operating business segments
6.1.2.Business performance
6.1.3.Key strategic moves and developments

6.2.BOC SCIENCES

6.2.1.Operating business segments
6.2.2.Business performance
6.2.3.Key strategic moves and developments

6.3.MANUS AKTTEVA BIOPHARMA LLP

6.3.1.Operating business segments
6.3.2.Business performance
6.3.3.Key strategic moves and developments

6.4.CAYMAN CHEMICAL

6.4.1.Operating business segments
6.4.2.Business performance
6.4.3.Key strategic moves and developments

6.5.HYCULTEC GMBH

6.5.1.Operating business segments
6.5.2.Business performance
6.5.3.Key strategic moves and developments

6.6.ABCAM PLC

6.6.1.Operating business segments
6.6.2.Business performance
6.6.3.Key strategic moves and developments

6.7.SANTA CRUZ BIOTECHNOLOGY, INC.

6.7.1.Operating business segments
6.7.2.Business performance
6.7.3.Key strategic moves and developments

6.8.HÖLZEL BIOTECH

6.8.1.Operating business segments
6.8.2.Business performance
6.8.3.Key strategic moves and developments

6.9.CHANGZHOU PHARMACEUTICAL FACTORY

6.9.1.Operating business segments
6.9.2.Business performance
6.9.3.Key strategic moves and developments

6.10.ND PHARMA & BIOTECH COMPANY

6.10.1.Operating business segments
6.10.2.Business performance
6.10.3.Key strategic moves and developments